Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyager Therapeutics Inc VYGR

Healthcare Biotechnology
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel... see more

Recent & Breaking News (NDAQ:VYGR)

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease

GlobeNewswire 1 day ago

Voyager Reports Third Quarter 2024 Financial and Operating Results

GlobeNewswire 9 days ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

GlobeNewswire November 5, 2024

Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected

GlobeNewswire September 16, 2024

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

GlobeNewswire September 5, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 29, 2024

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

GlobeNewswire August 29, 2024

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

GlobeNewswire August 7, 2024

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire August 6, 2024

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

GlobeNewswire July 30, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 23, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 9, 2024

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

GlobeNewswire June 13, 2024

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

GlobeNewswire June 13, 2024

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease

GlobeNewswire May 16, 2024

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire May 13, 2024

Voyager Therapeutics Presents Data for Second-Generation, TRACER(TM)-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

GlobeNewswire May 8, 2024

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

GlobeNewswire May 6, 2024

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

GlobeNewswire April 22, 2024